Yongqing Liu

Structure-BasedDesign and Optimization of Onradivir-DerivedPB2 Inhibitors for the Treatment of Influenza A

Abstract Influenza A remains a major seasonal public health burden. With the approval of onradivir, PB2 has emerged as an attractive antiviral target due to its unique and conserved structural features. Herein, using onradivir as the lead, we employed bioisosteric replacement str...